Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 11/20 | 0.41 |
| ▸ | MLNR | O43193 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16962506 | 1.00 | APP (0.44) | APPGPR183MLNRMEN1KMT2A | |
| SCHEMBL16962502 | 1.00 | APP (0.44) | APPGPR183MLNRMEN1KMT2A | |
| SCHEMBL21313914 | 0.86 | APP (0.40) | APPGPR183MLNRMAOAACHE | |
| SCHEMBL16962509 | 0.86 | APP (0.40) | APPGPR183MLNRMAOAACHE | |
| SCHEMBL21323087 | 0.85 | GPR183 (0.50) | APPGPR183 | |
| SCHEMBL21323088 | 0.85 | GPR183 (0.50) | APPGPR183 | |
| SCHEMBL16963641 | 0.85 | GPR183 (0.50) | APPGPR183 | |
| SCHEMBL16963638 | 0.85 | GPR183 (0.50) | APPGPR183 | |
| SCHEMBL17311095 | 0.85 | NAMPT (0.50) | GPR183MEN1KMT2AACHE | |
| SCHEMBL21323332 | 0.85 | NAMPT (0.50) | GPR183MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |